Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: BREAST NEOPLASMS - DRUG THERAPY , . Treffer: 133

2020

Bjelic-Radisic, V; Cardoso, F; Cameron, D; Brain, E; Kuljanic, K; da Costa, RA; Conroy, T; Inwald, EC; Serpentini, S; Pinto, M; Weis, J; Morag, O; Lindviksmoen Astrup, G; Tomaszweksi, KA; Pogoda, K; Sinai, P; Sprangers, M; Aaronson, N; Velikova, G; Greimel, E; Arraras, J; Bottomley, A; EORTC Quality of Life Group and Breast Cancer Group An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.
Ann Oncol. 2020; 31(2):283-288 Doi: 10.1016/j.annonc.2019.10.027
Web of Science PubMed FullText FullText_MUG

 

Dubsky, PC; Singer, CF; Egle, D; Wette, V; Petru, E; Balic, M; Pichler, A; Greil, R; Petzer, AL; Bago-Horvath, Z; Fesl, C; Meek, SM; Kronenwett, R; Rudas, M; Gnant, M; Filipits, M; Austrian Breast and Colorectal Cancer Study Group The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Eur J Cancer. 2020; 134:99-106 Doi: 10.1016/j.ejca.2020.04.020 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Hurvitz, SA; Martin, M; Press, MF; Chan, D; Fernandez-Abad, M; Petru, E; Rostorfer, R; Guarneri, V; Huang, CS; Barriga, S; Wijayawardana, S; Brahmachary, M; Ebert, PJ; Hossain, A; Liu, J; Abel, A; Aggarwal, A; Jansen, VM; Slamon, DJ Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
CLIN CANCER RES. 2020; 26(3): 566-580. Doi: 10.1158/1078-0432.CCR-19-1425 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Lord, SR; Collins, JM; Cheng, WC; Haider, S; Wigfield, S; Gaude, E; Fielding, BA; Pinnick, KE; Harjes, U; Segaran, A; Jha, P; Hoefler, G; Pollak, MN; Thompson, AM; Roy, PG; English, R; Adams, RF; Frezza, C; Buffa, FM; Karpe, F; Harris, AL Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
Br J Cancer. 2020; 122(2):258-265 Doi: 10.1038/s41416-019-0665-5 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stöger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Maria Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M; Austrian Breast & Colorectal Cancer Study Group Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Eur J Cancer. 2020; 132:43-52 Doi: 10.1016/j.ejca.2020.03.018
Web of Science PubMed FullText FullText_MUG

 

Steger, GG; Egle, D; Bartsch, R; Pfeiler, G; Petru, E; Greil, R; Helfgott, R; Marth, C; Öhler, L; Hubalek, M; Lang, A; Tinchon, C; Haslbauer, F; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Gnant, M Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Breast. 2020; 50:64-70 Doi: 10.1016/j.breast.2020.01.035 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2019

Vo, DH; Hartig, R; Weinert, S; Haybaeck, J; Nass, N G-Protein-Coupled Estrogen Receptor (GPER)-Specific Agonist G1 Induces ER Stress Leading to Cell Death in MCF-7 Cells.
Biomolecules. 2019; 9(9): Doi: 10.3390/biom9090503 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Cserni, G; Zombori, T; Andreu, X; Bianchi, S; Regitnig, P; Amendoeira, I; Balmativola, D; Kovács, A; Cordoba, A; Reiner, A; Kulka, J; Kaya, H; Liepniece-Karele, I; Quinn, C; Kővári, B Is Regression after Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Different in Sentinel and Non-sentinel Nodes?
Pathol Oncol Res. 2018; 24(1):167-170 Doi: 10.1007/s12253-017-0229-z [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Schramm, A; Schochter, F; Friedl, TWP; de Gregorio, N; Andergassen, U; Alunni-Fabbroni, M; Trapp, E; Jaeger, B; Heinrich, G; Camara, O; Decker, T; Ober, A; Mahner, S; Fehm, TN; Pantel, K; Fasching, PA; Schneeweiss, A; Janni, W; Rack, BK; SUCCESS Study Group Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Clin Breast Cancer. 2017; 17(4):279-285 Doi: 10.1016/j.clbc.2016.11.008
Web of Science PubMed FullText FullText_MUG

 

Singer, CF; Tan, YY; Fitzal, F; Steger, GG; Egle, D; Reiner, A; Rudas, M; Moinfar, F; Gruber, C; Petru, E; Bartsch, R; Tendl, KA; Fuchs, D; Seifert, M; Exner, R; Balic, M; Bago-Horvath, Z; Filipits, M; Gnant, M; Austrian Breast and Colorectal Cancer Study Group Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.
Clin Cancer Res. 2017; 23(14):3676-3683 Doi: 10.1158/1078-0432.CCR-16-2373 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Trapp, E; Steidl, J; Rack, B; Kupka, MS; Andergassen, U; Jückstock, J; Kurt, A; Vilsmaier, T; de Gregorio, A; de Gregorio, N; Tzschaschel, M; Lato, C; Polasik, A; Tesch, H; Schneeweiss, A; Beckmann, MW; Fasching, PA; Janni, W; Müller, V Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Breast. 2017; 35(1):130-135 Doi: 10.1016/j.breast.2017.07.007 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Hepp, P; Andergassen, U; Jäger, B; Trapp, E; Alunni-Fabbroni, M; Friedl, TW; Hecker, N; Lorenz, R; Fasching, P; Schneeweiss, A; Fehm, T; Janni, W; Rack, B Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Anticancer Res. 2016; 36(9):4771-4776 Doi: 10.21873/anticanres.11034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Ignatiadis, M; Rack, B; Rothé, F; Riethdorf, S; Decraene, C; Bonnefoi, H; Dittrich, C; Messina, C; Beauvois, M; Trapp, E; Goulioti, T; Tryfonidis, K; Pantel, K; Repollet, M; Janni, W; Piccart, M; Sotiriou, C; Litiere, S; Pierga, JY Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.
Eur J Cancer. 2016; 63(10):97-104 Doi: 10.1016/j.ejca.2016.04.024
Web of Science PubMed FullText FullText_MUG

 

Rack, B; Jückstock, J; Trapp, E; Weissenbacher, T; Alunni-Fabbroni, M; Schramm, A; Widschwendter, P; Lato, K; Zwingers, T; Lorenz, R; Tesch, H; Schneeweiss, A; Fasching, P; Mahner, S; Beckmann, MW; Lichtenegger, W; Janni, W; SUCCESS Study Group CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Tumour Biol. 2016; 37(10):13769-13775 Doi: 10.1007/s13277-016-5171-2
Web of Science PubMed FullText FullText_MUG

 

Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281 Doi: 10.1007/s00404-015-3879-7
Web of Science PubMed FullText FullText_MUG

 

Sigl, V; Owusu-Boaitey, K; Joshi, PA; Kavirayani, A; Wirnsberger, G; Novatchkova, M; Kozieradzki, I; Schramek, D; Edokobi, N; Hersl, J; Sampson, A; Odai-Afotey, A; Lazaro, C; Gonzalez-Suarez, E; Pujana, MA; Cimba, F; Heyn, H; Vidal, E; Cruickshank, J; Berman, H; Sarao, R; Ticevic, M; Uribesalgo, I; Tortola, L; Rao, S; Tan, Y; Pfeiler, G; Lee, EY; Bago-Horvath, Z; Kenner, L; Popper, H; Singer, C; Khokha, R; Jones, LP; Penninger, JM RANKL/RANK control Brca1 mutation- .
Cell Res. 2016; 26(7):761-774 Doi: 10.1038/cr.2016.69 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Zhang, F; Wang, X; Xu, X; Li, M; Zhou, J; Wang, W Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Eur J Pharm Sci. 2016; 92(36):11-21 Doi: 10.1016/j.ejps.2016.06.017
Web of Science PubMed FullText FullText_MUG

 

2015

Benhaim, L; Zhang, W; Wakatsuki, T; Yang, D; Gerger, A; Bohanes, P; Paez, D; Loupakis, F; LaBonte, MJ; Ning, Y; El-Khoueiry, R; Ladner, R; Wilson, P; Zhang, H; Giamas, G; Stebbing, J; Lenz, HJ Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.
Pharmacogenomics J. 2015; 15(3):235-240 Doi: 10.1038/tpj.2014.58
Web of Science PubMed FullText FullText_MUG

 

Bossuyt, V; Provenzano, E; Symmans, WF; Boughey, JC; Coles, C; Curigliano, G; Dixon, JM; Esserman, LJ; Fastner, G; Kuehn, T; Peintinger, F; von Minckwitz, G; White, J; Yang, W; Badve, S; Denkert, C; MacGrogan, G; Penault-Llorca, F; Viale, G; Cameron, D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.
ANN ONCOL. 2015; 26(7): 1280-1291. Doi: 10.1093/annonc/mdv161 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Knauer, M; Moik, M; Jakesz, R; Seifert, M; Taucher, S; Bjelic-Radisic, V; Balic, M; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Selim, U; Fitzal, F; Hochreiner, G; Wette, V; Sevelda, P; Ploner, F; Bartsch, R; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Ann Oncol. 2015; 26(2):313-320 Doi: 10.1093/annonc/mdu544 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Pfeiler, G; Dubsky, PC; Hubalek, M; Greil, R; Jakesz, R; Wette, V; Balic, M; Haslbauer, F; Melbinger, E; Bjelic-Radisic, V; Artner-Matuschek, S; Fitzal, F; Marth, C; Sevelda, P; Mlineritsch, B; Steger, GG; Manfreda, D; Exner, R; Egle, D; Bergh, J; Kainberger, F; Talbot, S; Warner, D; Fesl, C; Singer, CF; Austrian Breast and Colorectal Cancer Study Group Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
LANCET. 2015; 386(9992): 433-443. Doi: 10.1016/S0140-6736(15)60995-3
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Sestak, I; Filipits, M; Dowsett, M; Balic, M; Lopez-Knowles, E; Greil, R; Dubsky, P; Stoeger, H; Rudas, M; Jakesz, R; Ferree, S; Cowens, JW; Nielsen, T; Schaper, C; Fesl, C; Cuzick, J Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
Ann Oncol. 2015; 26(8):1685-1691 Doi: 10.1093/annonc/mdv215 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Peintinger, F; Sinn, B; Hatzis, C; Albarracin, C; Downs-Kelly, E; Morkowski, J; Gould, R; Symmans, WF Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.
MODERN PATHOL. 2015; 28(7): 913-920. Doi: 10.1038/modpathol.2015.53 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science PubMed

 

Suppan, C; Bjelic-Radisic, V; La Garde, M; Groselj-Strele, A; Eberhard, K; Samonigg, H; Loibner, H; Dandachi, N; Balic, M Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.
BMC Cancer. 2015; 15:1027-1027 Doi: 10.1186/s12885-015-2005-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Aigner, B; Bauernhofer, T; Petru, E; Niederkorn, A; Arzberger, EJ; Richtig, E Complete recovery of a wide local reaction by the use of dexrazoxane 72 hours after epirubicin extravasation: case report and review of the literature.
Dermatology. 2014; 229(4):288-292 Doi: 10.1159/000365391 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Filipits, M; Nielsen, TO; Rudas, M; Greil, R; Stöger, H; Jakesz, R; Bago-Horvath, Z; Dietze, O; Regitnig, P; Gruber-Rossipal, C; Müller-Holzner, E; Singer, CF; Mlineritsch, B; Dubsky, P; Bauernhofer, T; Hubalek, M; Knauer, M; Trapl, H; Fesl, C; Schaper, C; Ferree, S; Liu, S; Cowens, JW; Gnant, M; Austrian Breast and Colorectal Cancer Study Group The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Clin Cancer Res. 2014; 20(5):1298-1305 Doi: 10.1158/1078-0432.CCR-13-1845 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Austrian Breast and Colorectal Cancer Study Group Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol. 2014; 25(2):339-345 Doi: 10.1093/annonc/mdt494 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Luschin, G; Habersack, M Oral information about side effects of endocrine therapy for early breast cancer patients at initial consultation and first follow-up visit: an online survey.
Health Commun. 2014; 29(4):421-426 Doi: 10.1080/10410236.2012.743096
Web of Science PubMed FullText FullText_MUG

 

Peintinger, F Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?
Curr Opin Obstet Gynecol. 2014; 26(1):21-26 Doi: 10.1097/GCO.0000000000000041
Web of Science PubMed FullText FullText_MUG

 

Province, MA; Goetz, MP; Brauch, H; Flockhart, DA; Hebert, JM; Whaley, R; Suman, VJ; Schroth, W; Winter, S; Zembutsu, H; Mushiroda, T; Newman, WG; Lee, MT; Ambrosone, CB; Beckmann, MW; Choi, JY; Dieudonné, AS; Fasching, PA; Ferraldeschi, R; Gong, L; Haschke-Becher, E; Howell, A; Jordan, LB; Hamann, U; Kiyotani, K; Krippl, P; Lambrechts, D; Latif, A; Langsenlehner, U; Lorizio, W; Neven, P; Nguyen, AT; Park, BW; Purdie, CA; Quinlan, P; Renner, W; Schmidt, M; Schwab, M; Shin, JG; Stingl, JC; Wegman, P; Wingren, S; Wu, AH; Ziv, E; Zirpoli, G; Thompson, AM; Jordan, VC; Nakamura, Y; Altman, RB; Ames, MM; Weinshilboum, RM; Eichelbaum, M; Ingle, JN; Klein, TE; International Tamoxifen Pharmacogenomics Consortium CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.
Clin Pharmacol Ther. 2014; 95(2):216-227 Doi: 10.1038/clpt.2013.186 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Rugani, P; Luschin, G; Jakse, N; Kirnbauer, B; Lang, U; Acham, S Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer.
Clin Oral Investig. 2014; 18(2):401-407 Doi: 10.1007/s00784-013-1012-5
Web of Science PubMed FullText FullText_MUG

 

Singer, CF; Bennink, HJ; Natter, C; Steurer, S; Rudas, M; Moinfar, F; Appels, N; Visser, M; Kubista, E Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer.
Carcinogenesis. 2014; 35(11):2447-2451 Doi: 10.1093/carcin/bgu144 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Steger, GG; Greil, R; Lang, A; Rudas, M; Fitzal, F; Mlineritsch, B; Hartmann, BL; Bartsch, R; Melbinger, E; Hubalek, M; Stoeger, H; Dubsky, P; Ressler, S; Petzer, AL; Singer, CF; Muss, C; Jakesz, R; Gampenrieder, SP; Zielinski, CC; Fesl, C; Gnant, M Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
ANN ONCOL. 2014; 25(2): 366-371. Doi: 10.1093/annonc/mdt508 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Winder, T; Giamas, G; Wilson, PM; Zhang, W; Yang, D; Bohanes, P; Ning, Y; Gerger, A; Stebbing, J; Lenz, HJ Insulin-like growth factor receptor polymorphism defines clinical outcome in estrogen receptor-positive breast cancer patients treated with tamoxifen.
Pharmacogenomics J. 2014; 14(1):28-34 Doi: 10.1038/tpj.2013.8
Web of Science PubMed FullText FullText_MUG

 

2013

AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members; Hoffmann, J; Souchon, R; Lebeau, A; Öhlschlegel, C; Gruber, G; Rageth, C; Weber, W; Harbeck, N; Janni, W; Kreipe, H; Fitzal, F; Resch, A; Bago-Horvath, Z; Peintinger, F German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer.
Eur J Cancer. 2013; 49(10): 2277-2283. Doi: 10.1016/j.ejca.2013.01.034
Web of Science PubMed FullText FullText_MUG

 

Aigner, B; Plötz, SG; Schaller, G Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature.
Wien Med Wochenschr. 2013; 163(21-22): 495-498. Doi: 10.1007/s10354-013-0242-0 (- Case Report)
PubMed FullText FullText_MUG

 

Dubsky, P; Filipits, M; Jakesz, R; Rudas, M; Singer, CF; Greil, R; Dietze, O; Luisser, I; Klug, E; Sedivy, R; Bachner, M; Mayr, D; Schmidt, M; Gehrmann, MC; Petry, C; Weber, KE; Kronenwett, R; Brase, JC; Gnant, M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Ann Oncol. 2013; 24(3):640-647 Doi: 10.1093/annonc/mds334 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Gnant, M; Pfeiler, G; Stöger, H; Mlineritsch, B; Fitzal, F; Balic, M; Kwasny, W; Seifert, M; Stierer, M; Dubsky, P; Greil, R; Steger, G; Samonigg, H; Fesl, C; Jakesz, R The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.
Br J Cancer. 2013; 109(3):589-596 Doi: 10.1038/bjc.2013.367 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pfeiler, G; Stöger, H; Dubsky, P; Mlineritsch, B; Singer, C; Balic, M; Fitzal, F; Moik, M; Kwasny, W; Selim, U; Renner, K; Ploner, F; Steger, GG; Seifert, M; Hofbauer, F; Sandbichler, P; Samonigg, H; Jakesz, R; Greil, R; Fesl, C; Gnant, M; ABCSG Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.
Br J Cancer. 2013; 108(7):1408-1414 Doi: 10.1038/bjc.2013.114 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2012

Dubsky, PC; Jakesz, R; Mlineritsch, B; Pöstlberger, S; Samonigg, H; Kwasny, W; Tausch, C; Stöger, H; Haider, K; Fitzal, F; Singer, CF; Stierer, M; Sevelda, P; Luschin-Ebengreuth, G; Taucher, S; Rudas, M; Bartsch, R; Steger, GG; Greil, R; Filipcic, L; Gnant, M Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2012; 30(7):722-728 Doi: 10.1200/JCO.2011.36.8993 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Fröhlich, E; Wahl, R Do antidiabetic medications play a specific role in differentiated thyroid cancer compared to other cancer types?
Diabetes Obes Metab. 2012; 14(3): 204-213. Doi: 10.1111/j.1463-1326.2011.01491.x
Web of Science PubMed FullText FullText_MUG

 

Labonte, MJ; Wilson, PM; Yang, D; Zhang, W; Ladner, RD; Ning, Y; Gerger, A; Bohanes, PO; Benhaim, L; El-Khoueiry, R; El-Khoueiry, A; Lenz, HJ The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Ann Oncol. 2012; 23(6):1455-1464 Doi: 10.1093/annonc/mdr445 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Mazouni, C; Reitsamer, R; Rimareix, F; Stranzl, H; Uzan, C; Garbay, JR; Delaloge, S; Peintinger, F; The positive non-sentinel status is not the main decisional factor for chemotherapy assignment in breast cancer with micrometastatic disease in the sentinel lymph node.
J Surg Oncol. 2012; 106(6):703-707 Doi: 10.1002/jso.23188
Web of Science PubMed FullText FullText_MUG

 

Petru, E; Zeimet, AG; Sevelda, P; Seifert, M; Singer, C; Hubalek, M; Angleitner-Boubenizek, L; Speiser, P; Benedicic, C; Stummvoll, W; Reinthaller, A; Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.
Wien Klin Wochenschr. 2012; 124(11-12):412-418 Doi: 10.1007/s00508-012-0185-2
Web of Science PubMed FullText FullText_MUG

 

Szkandera, J; Absenger, G; Dandachi, N; Regitnig, P; Lax, S; Stotz, M; Samonigg, H; Renner, W; Gerger, A Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Mol Genet Genomics. 2012; 287(9):755-764 Doi: 10.1007/s00438-012-0715-7
Web of Science PubMed FullText FullText_MUG

 

2011

Gnant, M; Mlineritsch, B; Stoeger, H; Luschin-Ebengreuth, G; Heck, D; Menzel, C; Jakesz, R; Seifert, M; Hubalek, M; Pristauz, G; Bauernhofer, T; Eidtmann, H; Eiermann, W; Steger, G; Kwasny, W; Dubsky, P; Hochreiner, G; Forsthuber, EP; Fesl, C; Greil, R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.
Lancet Oncol. 2011; 12(7):631-641 Doi: 10.1016/S1470-2045(11)70122-X
Web of Science PubMed FullText FullText_MUG

 

Parmar, S; Stingl, JC; Huber-Wechselberger, A; Kainz, A; Renner, W; Langsenlehner, U; Krippl, P; Brockmöller, J; Haschke-Becher, E Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.
Breast Cancer Res. 2011; 13(3):R57-R57 Doi: 10.1186/bcr2894 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pfeiler, G; Königsberg, R; Fesl, C; Mlineritsch, B; Stoeger, H; Singer, CF; Pöstlberger, S; Steger, GG; Seifert, M; Dubsky, P; Taucher, S; Samonigg, H; Bjelic-Radisic, V; Greil, R; Marth, C; Gnant, M Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.
J Clin Oncol. 2011; 29(19):2653-2659 Doi: 10.1200/JCO.2010.33.2585 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2010

Hoffmann, K; Franz, C; Hinz, U; Schirmacher, P; Herfarth, C; Eichbaum, M; Büchler, MW; Schemmer, P Liver resection for multimodal treatment of breast cancer metastases: identification of prognostic factors.
Ann Surg Oncol. 2010; 17(6):1546-1554 Doi: 10.1245/s10434-010-0931-5
Web of Science PubMed FullText FullText_MUG

 

Weitere 50 Treffer anzeigen
© Med Uni Graz Impressum